Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott J. Rodig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Scott Rodig and Donna Neuberg.
Connection Strength

2.614
  1. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364.
    View in: PubMed
    Score: 0.231
  2. Reply to Z. Wu et al. J Clin Oncol. 2018 09 01; 36(25):2657.
    View in: PubMed
    Score: 0.191
  3. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430.
    View in: PubMed
    Score: 0.182
  4. Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016 11; 4(11):910-916.
    View in: PubMed
    Score: 0.170
  5. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
    View in: PubMed
    Score: 0.164
  6. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. Am J Clin Pathol. 2016 Feb; 145(2):166-79.
    View in: PubMed
    Score: 0.162
  7. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn. 2015 Jan; 17(1):19-30.
    View in: PubMed
    Score: 0.149
  8. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012; 7(4):e33813.
    View in: PubMed
    Score: 0.125
  9. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008 Jun 01; 14(11):3338-44.
    View in: PubMed
    Score: 0.095
  10. Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clin Cancer Res. 2021 09 15; 27(18):5072-5083.
    View in: PubMed
    Score: 0.059
  11. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
    View in: PubMed
    Score: 0.059
  12. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525.
    View in: PubMed
    Score: 0.057
  13. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020 09; 26(9):1468-1479.
    View in: PubMed
    Score: 0.056
  14. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019 12 01; 37(34):3291-3299.
    View in: PubMed
    Score: 0.052
  15. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica. 2020 05; 105(5):1361-1368.
    View in: PubMed
    Score: 0.052
  16. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
    View in: PubMed
    Score: 0.050
  17. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
    View in: PubMed
    Score: 0.048
  18. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
    View in: PubMed
    Score: 0.048
  19. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018 08 23; 132(8):825-836.
    View in: PubMed
    Score: 0.048
  20. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
    View in: PubMed
    Score: 0.047
  21. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
    View in: PubMed
    Score: 0.047
  22. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 04 01; 36(10):942-950.
    View in: PubMed
    Score: 0.047
  23. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.045
  24. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Adv. 2016 Nov 29; 1(1):84-92.
    View in: PubMed
    Score: 0.043
  25. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016 08 10; 34(23):2690-7.
    View in: PubMed
    Score: 0.041
  26. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013 Jul 16; 2:e00825.
    View in: PubMed
    Score: 0.034
  27. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
    View in: PubMed
    Score: 0.034
  28. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013 Jun 10; 23(6):826-38.
    View in: PubMed
    Score: 0.034
  29. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr; 98(4):615-9.
    View in: PubMed
    Score: 0.032
  30. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
    View in: PubMed
    Score: 0.032
  31. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012 Mar 20; 21(3):362-73.
    View in: PubMed
    Score: 0.031
  32. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
    View in: PubMed
    Score: 0.031
  33. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012 Mar 15; 18(6):1611-8.
    View in: PubMed
    Score: 0.031
  34. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55.
    View in: PubMed
    Score: 0.030
  35. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A. 2011 Feb 15; 108(7):2873-8.
    View in: PubMed
    Score: 0.029
  36. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct 28; 116(17):3268-77.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.